South Korean drugmaker Celltrion today announced the first batch of results from its phase two COVID-19 treatment clinical trial.
Results showed it could reduce recovery time and decreased the chances of being severely ill by 54 percent.
For moderate cases among patients aged 50 or over it’s 68 percent.
Tests also showed that recovery time is three days faster than the placebo and for those 50 or over with moderate symptoms it’s five to six days faster.
No one died during the trial or suffered adverse reactions.
If approved, Celltrion’s treatment will be South Korea’s first COVID-19 treatment.
Results showed it could reduce recovery time and decreased the chances of being severely ill by 54 percent.
For moderate cases among patients aged 50 or over it’s 68 percent.
Tests also showed that recovery time is three days faster than the placebo and for those 50 or over with moderate symptoms it’s five to six days faster.
No one died during the trial or suffered adverse reactions.
If approved, Celltrion’s treatment will be South Korea’s first COVID-19 treatment.
Reporter : tommyjang@arirang.com
Source Link
This page is made available thanks to China Press Release by Topic News